scispace - formally typeset
M

Marc Ladanyi

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  39
Citations -  22650

Marc Ladanyi is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Guideline & Gefitinib. The author has an hindex of 26, co-authored 39 publications receiving 17744 citations. Previous affiliations of Marc Ladanyi include Kettering University & Baylor College of Medicine.

Papers
More filters
Journal ArticleDOI

The cancer genome atlas pan-cancer analysis project

John N. Weinstein, +379 more
- 01 Oct 2013 - 
TL;DR: The Pan-Cancer initiative compares the first 12 tumor types profiled by TCGA with a major opportunity to develop an integrated picture of commonalities, differences and emergent themes across tumor lineages.
Journal ArticleDOI

Genomic Classification of Cutaneous Melanoma

Rehan Akbani, +351 more
- 18 Jun 2015 - 
TL;DR: This clinicopathological and multi-dimensional analysis suggests that the prognosis of melanoma patients with regional metastases is influenced by tumor stroma immunobiology, offering insights to further personalize therapeutic decision-making.
Journal ArticleDOI

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, +311 more
- 05 Nov 2015 - 
TL;DR: The Cancer Genome Atlas (TCGA) has been used for a comprehensive molecular analysis of primary prostate carcinomas as discussed by the authors, revealing substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course.
Journal ArticleDOI

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Nishant Agrawal, +242 more
- 23 Oct 2014 - 
TL;DR: The genomic landscape of 496 PTCs is described and a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties is proposed, which has the potential to improve their pathological classification and better inform the management of the disease.
Journal ArticleDOI

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

TL;DR: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type.